Pyridine-2-azo-p-dimethylanaline cephalosporin (PADAC), a chromogenic reagent which is purple and changes to yellow upon cleavage of its beta-lactam ring, was evaluated in comparison with other chromogenic cephalosporins. PADAC exhibited little antimicrobial activity against gram-negative bacteria, but did have good activity (minimum inhibitory concentration, 0.12 to 0.5 ,ug/ml) against Staphylococcus aureus, a quality comparable to nitrocefin. Nitrocefin, however, demonstrated an unexpected and uniquely potent activity against Streptococculs faecalis (minimum inhibitory concentration, -0.06 to 0.12 p.g/ml). The relative hydrolysis rate of PADAC when subjected to six different beta-lactamases was substantially greater than that of cephacetrile, but less than that of nitrocefin. The relative hydrolysis rates of PADAC and nitrocefin were comparable with type Illa beta-lactamase and that derived from Bacillus cereus. The inhibition of betalactamase hydrolysis of the chromogenic cephalosporin substrates by six enzymestable inhibitors was generally greater with PADAC than with nitrocefin. Unlike nitrocefin, PADAC mixed with 50% human serum or various broth culture media showed no evidence of color change or degradation over several hours. The subsequent enzyme hydrolysis rates of such mixtures were the same as in phosphate buffer. Beta-lactamase-containing bacterial suspensions and clinical specimens containing such bacteria produced positive visual and spectrophotometric color changes when mixed with PADAC or nitrocefin. Although color changes occurred more slowly with PADAC than with nitrocefin, PADAC was not adversely influenced (non-enzyme-related color change) by the protein content of specimens. PADAC appears to be a promising alternative for betalactamase diagnostic testing in the clinical and research microbiology laboratory.
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Pyridine-2-azo-p-dimethylanaline chromophore 3-substituted cephalosporin (PADAC) is a new chromogenic beta-lactam developed by Hoechst AG (Frankfurt, West Germany) that has a distinct color change from purple to clear yellow concomitant with the cleaving of the beta-lactam ring (19) (Fig. 1) . Other reported chromogenic cephalosporin reagents have included nitrocefin (formerly 87/312) and the parenteral therapeutic agent cephacetrile (14, 18) . These latter compounds have a light-yellow color in the absence of beta-lactamase, but rapidly convert to red when the beta-lactam ring is broken (14, 18) . Both have been applied to the monitoring of beta-lactamase enzyme kinetics in the research setting, along with cephaloridine, and also to the rapid screening of clinical isolates for enzyme production (6a-8). The limited availability of nitrocefin and the lower sensitivity of the cephacetrile reagent have discouraged the wide use of these drugs as clinical diagnostics.
In the mid-1970s, beta-lactamases were detected in heretofore beta-lactam-susceptible microorganisms (2, 15, 20) . These genetic events stimulated the simultaneous development of beta-lactamase refractory antimicrobial agents (5) (6) (7) 12) and simple, easy to use beta-lactamase detection tests (1, 8, 9, 14, 17, 21 
RESULTS
The antimicrobial activities of PADAC, nitrocefin, cephacetrile, and cephaloridine were tested by reference microdilution methods in a 12-dilution schedule ranging from 0.06 to 128 ,ug/ml ( Table 1 ). The 138 gram-negative isolates were generally resistant (median MICs, >128 ,ug/ml) to the inhibiting effects of PADAC and nitrocefin. Only rare strains of Providencia rettgeri had nitrocefin MICs of 8 ,g/ml. Cephacetrile and cephaloridine possess a spectrum similar to cephalothin, thus inhibiting only Escherichia coli, Klebsiella spp., and Proteus mirabilis among the Enterobacteriaceae and, also, Staphylococcus aureus. PADAC and nitrocefin were comparable to cephaloridine in anti-staphylococcal activity (median MICs, 0.25 ,ug/ml). Penicillinase-producing S. aureus strains had median MICs four-and .eightfold higher than penicillinase-negative strains for PADAC and nitrocefin, respectively. This indicates a partial susceptibility of these cephalosporins to the staphylococcal beta-lactamase. An unexpected finding was the very low nitrocefin MIC (range, s0.06 to 0.12 ,ug/ml) for enterococci. The other reference cephalosporin MICs for Streptococcus faecalis were .16 ,ug/ml, consistent with other cephalosporin drugs. Table 2 shows the results of spectrophotometric beta-lactam hydrolysis studies, using six beta-lactamases from reference bacteria or commercial sources. The color change for PADAC was from purple (lambda maximum, ca. 570 nm) to a clear yellow (lambda maximum, ca. 465 nm). This change was monitored at 570 nm for these studies, and the resulting scans before and after beta-lactamase (type la, Enterobacter cloacae) addition to the reaction mixture are shown in Fig. 2 Table 3 and Fig. 3 demonstrate the results of using nitrocefin and PADAC as beta-lactamaselabile substrates in enzyme inhibition studies. Six beta-lactamase-stable inhibitors were selected (cefotaxime, ceftazidime, CP 45,899, dicloxacillin, HR221, and SCH29482) for their variability of inhibitory effect, particularly on type I beta-lactamases (5, 6, 16) . At least one drug had a significant inhibitory effect (>50% of relative hydrolysis rate) for each enzyme (Table 3) . For nearly all enzymes tested the inhibitor was more active against the PADAC hydrolysis than against that of nitrocefin. Only CP 45,899 versus type II and the B. cereus gram-positive enzyme slightly reversed this trend. Figure 3 graphically shows that beta-lactamase inhibitors achieve significant effects at lower percent concentrations for PADAC than for the nitrocefin substrate. Approximately a 10-fold difference is evident for HR221, SCH29482, and ceftazidime, and CP 45,891 produces a 50% inhibition of PADAC hydrolysis at an 8% concentration of substrate compared with a >200% concentration needed to inhibit nitrocefin hydrolysis. The comparisons for the very potent type I inhibitors dicloxacillin and cefotaxime were difficult to assess due to their extreme effects below 0. (2, 8, 15, 20) . Among these, H. influenzae and N. gonorrhoeae (penicillinaseproducing strains) produce a large number of serious infections in children and adults, respectively. Early recognition of these beta-lactamase-producing strains allows the proper selection of antimicrobial agents (or deletion of unusable drugs) and a rapid follow-up of patient contacts, minimizing widespread circulation of penicillinase-producing N. gonorrhoeae in the community. The latter problem has been reemphasized in the recent report of a 0.6% incidence of penicillinase-producing N. gonorrhoeae in Florida (3).
Rapid colorimetric diagnostic tests capable of detecting beta-lactamase have been developed and include an acidometric penicillinase test (17, 21) , iodometric techniques (1, 9) , and chromogenic reagents from basic cephalosporin structures (14) . Varying enzyme detection susceptibilities for these tests are well known, and it is also known that they best correlate to the type of substrate beta-lactam used. Among the most sensitive tests has been the nitrocefin (87/312) chromogenic cephalosporin developed by Glaxo Research Group, Ltd., but its use has been generally limited to research laboratories due to inconsistent availability as a diagnostic. Thus, PADAC, a similar cephalosporin chromophore, appears to be a welcome addition to the diagnostic beta-lactamase reagents as a powder (Calbiochem-Behring) or on dipsticks (Behringwerke).
PADAC has an easily seen color change, allowing application by most clinical microbiology laboratories. This reagent used as a test solution or on paper strips readily detected betalactamase in culture and in clinical specimens in our studies and those reported by others (C. Thornsberry (4) . PADAC can also be used as the beta-lactamlabile substrate for inhibition studies (6a, 7) . Both nitrocefin and PADAC can be monitored in the non-UV range for those comparative analyses, in contrast to cephaloridine (5, 6, 13) . Here PADAC may be a better substrate due to its decreased enzyme affinity compared with nitrocefin or cephaloridine (data not shown) when in combination with other beta-lactams used as inhibitors.
Application to the direct examination of clinically infected fluids and other physiological materials seems practical due to the apparent lack of PADAC interaction with normal human serum constituents. Schindler and Huber describe the application of PADAC type I (Enterobacter cloacae P99) beta-lactamase hydrolysis to the quantitative measurement of those inhibiting beta-lactams down to the nanogram level on non-UV instruments (19) . Similarly, the detection and quantitation of beta-lactamases in body fluids regardless of protein content seems both feasible and desirable (further studies in progress).
In (19) . Like nitrocefin, PADAC is a poor antimicrobial agent against gram-negative species, but has some activity against S. aureus. Representative beta-lactamase extracts and whole-cell suspensions (cultures and clinical fluids) produced a visual and spectrophotometric PADAC color change at a rate slower than nitrocefin. Both PADAC and nitrocefin were excellent substrates for beta-lactamase inhibition studies. PADAC should be a welcome addition to the beta-lactamase diagnostic tests that are urgently needed in the clinical microbiology laboratory and to the researcher as a reference beta-lactamase-labile chromogenic substrate.
